Company: CERO
Filing Date: 2025-11-20
Form Type: 424B3
Source: 0001213900-25-113118
Chunk: 4

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-20
Form: 424B3
Chunk 4
---
.                       | Risk Factors                                                                                                                                                                                                                                                                                      |   45 |
| Item 2.                        | Unregistered Sales of Equity Securities and Use of Proceeds                                                                                                                                                                                                                                       |   51 |
| Item 3.                        | Defaults Upon Senior Securities                                                                                                                                                                                                                                                                   |   51 |
| Item 4.                        | Mine Safety Disclosures                                                                                                                                                                                                                                                                           |   51 |
| Item 5.                        | Other Information                                                                                                                                                                                                                                                                                 |   51 |
| Item 6.                        | Exhibits                                                                                                                                                                                                                                                                                          |   52 |
| SIGNATURES                     |                                                                                                                                                                                                                                                                                                   |   54 |

<div align='center'>i

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</div>

This Quarterly Report on
Form 10-Q (this “Quarterly Report”) contains forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”). All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding
our future results of operations and financial position, business strategy, drug candidates, planned preclinical studies and clinical
trials, results of preclinical studies, clinical trials, research and development (“R&D”) costs, regulatory approvals,
timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements.
These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond our control
and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements
expressed or implied by the forward-looking statements.

In some cases, you can identify
forward-looking statements by terms such as “may,” “will,” “should,” “would,” “expect,”
“plan,” “anticipate,” “could,” “intend,” “target,” “project,”
“believe,” “estimate,” “predict,” “potential,” or “continue” or the negative
of these terms or other similar expressions. Forward-looking statements contained in this Quarterly Report include, but are not limited
to, statements about:

| ● | our financial performance; |

| ● | our ability to obtain additional cash and the sufficiency of our existing cash, cash equivalents and equity securities to fund our future operating expenses and capital expenditure requirements, including the development and, if approved,